Health
FDA authorizes marketing of new device for short-term treatment of gait deficit in MS patients – News-Medical.Net
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate…
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS). The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older. The device, called Portable Neuromodulation Stimulator (PoNS), is a neuromuscular tongue stimulator that consists of a non-implantable apparatus…
-
Noosa News20 hours agoGirl on scooter dies in Laidley, motorbike rider killed in Gatton
-
Noosa News16 hours agoLaidley e-scooter death: Tragic new details after Summah Richards killed in freak accident
-
General20 hours agoBrisbane coach Michael Maguire backs Reece Walsh despite error handing Broncos defeat
-
General15 hours agoEaster drowning toll in NSW rises after fisherman swept off rocks in Sydney’s south